共 50 条
- [43] Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study REPLY JOURNAL OF UROLOGY, 2021, 206 (04): : 923 - 923
- [45] Efficacy and safety exposure–response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study Cancer Chemotherapy and Pharmacology, 2022, 89 : 629 - 641
- [46] PROSTATE-SPECIFIC ANTIGEN KINETICS IN PATIENTS WITH ADVANCED PROSTATE CANCER TREATED WITH APALUTAMIDE: RESULTS FROM THE TITAN AND SPARTAN STUDIES JOURNAL OF UROLOGY, 2021, 206 : E587 - E587
- [47] Prostate-specific antigen doubling time in metastatic castration-resistant prostate cancer: a clinically useful prognostic factor EJC SUPPLEMENTS, 2009, 7 (04): : 14 - 14
- [48] The prognostic importance of prostate-specific antigen in monitoring patients undergoing maximum androgen blockage for metastatic prostate cancer THESCIENTIFICWORLDJOURNAL, 2005, 5 : 118 - 124
- [50] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04): : 352 - 360